<DOC>
	<DOCNO>NCT01672879</DOCNO>
	<brief_summary>This study evaluate safety efficacy simtuzumab ( GS-6624 ) adult compensate cirrhosis due Non-Alcoholic Steatohepatitis ( NASH ) . It consist 2 phase : - Randomized Double-Blind Phase - Open Label Phase ( optional )</brief_summary>
	<brief_title>Simtuzumab ( GS-6624 ) Treatment Cirrhosis Due NASH</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Adult subject ( aged 1865 ) cirrhosis liver define Ishak fibrosis stage ≥ 5 Liver biopsy consistent NASH cryptogenic cirrhosis Exclusion cause liver disease include viral hepatitis alcoholic liver disease Must aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 10 x upper limit normal range ( ULN ) Must serum creatinine &lt; 2.0 mg/dL A negative serum pregnancy test require female subject childbearing potential All sexually active female subject childbearing potential must agree use protocol recommend method contraception heterosexual intercourse throughout study 90 day follow last dose study medication Lactating female must agree discontinue nurse start study treatment Male subject , vasectomize , require use barrier contraception ( condom plus spermicide ) heterosexual intercourse screen study completion 90 day follow last dose study drug Key Pregnant breast feed Any history hepatic decompensation include ascites , hepatic encephalopathy variceal bleed Weight reduction surgery past 5 year Positive hepatitis C virus ( HCV ) RNA Positive HBsAg Alcohol consumption great 21oz/week male 14oz/week female Positive urine screen amphetamine , cocaine opiate ( i.e . heroin , morphine ) screening . Subjects stable methadone buprenorphine maintenance treatment least 6 month prior screen may include study . Subjects positive urine drug screen due prescription opioidbased medication eligible prescription diagnosis review approved investigator Clinically significant cardiac disease History malignancy , nonmelanomatous skin cancer , within 5 year prior screen Major surgical procedure within 30 day prior screen presence open wound Known hypersensitivity investigation product formulation excipients History bleed diathesis within 6 month screen Unavailable followup assessment concern subject 's compliance protocol procedure ; Participation investigational trial drug device within 30 day prior screen Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>NASH</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>Compensated Liver disease</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>LOXL2</keyword>
	<keyword>Simtuzumab</keyword>
	<keyword>Nonalcoholic Steatohepatitis</keyword>
	<keyword>Hepatic venous pressure gradient</keyword>
	<keyword>HVPG</keyword>
	<keyword>NAFLD</keyword>
	<keyword>MRE</keyword>
	<keyword>Liver biopsy</keyword>
</DOC>